The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Abstract
BACKGROUND Obesity is a widespread and chronic condition that requires long-term management; research into additional targets to improve treatment outcomes remains a priority. This study aimed to investigate the safety, tolerability, and efficacy of glucagon receptor-GLP-1 receptor dual agonist survodutide (BI 456906) in obesity management. METHODS In this randomised, double-blind, placebo-controlled, dose-finding phase 2 trial conducted in 43 centres in 12 countries, we enrolled participants (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) and randomly assigned them by interactive response technology (1:1:1:1:1; stratified by sex) to subcutaneous survodutide (0·6, 2·4, 3·6, or 4·8 mg) or placebo once-weekly for 46 weeks (20 weeks dose escalation; 26 weeks dose maintenance). The primary endpoint was the percentage change in bodyweight from baseline to week 46. Primary analysis included the modified intention-to-treat population (defined as all randomly assigned patients who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint) and was based on the dose assigned at randomisation (planned treatment), including all data censored for COVID-19-related discontinuations; the sensitivity analysis was based on the actual dose received during maintenance phase (actual treatment) and included on-treatment data. Safety analysis included all participants who received at least one dose of study drug. The trial is registered with C…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“e14.9% (e16.9 to e13.0; with the 4.8 mg); e2.8% (e4.9 to e0.7; with placebo) (le Roux et al, 2024)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as le Roux et al, 2024
In the citing paper
“while phase 2 results for survodutide (4.8 mg weekly for 46 weeks) demonstrated an 18.7% reduction in bodyweight (vs. 2.3% with placebo) [36].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [36]
In the citing paper
“Moreover, the magnitude of WL with retatrutide also exceeded that seen with other pipeline multi-agonists such as CagriSema (cagrilintide, an amylin agonist, in combination with semaglutide), mazdutide and survodutide (Fig. 4) [8, 27, 35, 36, 45, 46, 49–53].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [36]
In the citing paper
“A phase 2 trial on survodutide (4 doses of 0.6, 2.4, 3.6, and 4.8 mg) (NCT04667377) compared to placebo in 387 adults with BMI !27 kg/m 2 showed mean (95% CI) changes in body weight from baseline to week 46 of e6.2% (e8.3 to e4.1; with the 0.6 mg); e12.5% (e14.5 to e10.5; with the 2.4 mg); e13.2% (e15.3 to e11.2; with the 3.6 mg); e14.9% (e16.9 to e13.0; with the 4.8 mg); e2.8% (e4.9 to e0.7; with”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as le Roux et al, 2024
In the citing paper
“At its highest dose of 4.8 mg, study participants lost 14.9% of their weight vs. 2.8% in the placebo group (Table 2).50”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [50]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Research works printed but not linked: 1
- Blüher, 2023, Dose-response effects on HbA1c and bodyweight reductions with a dual glucagon/GLP-1 receptor agonist, survodutide, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial, Diabetologia
Cited by
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
Metadata
- Authors
- le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M.
- Affiliations
- LMC Diabetes & Endocrinology (Canada) (CA)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Hennige, Anita M
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 12
- Issue
- 3
- Pages
- 162-173
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4391544195
- Cited by
- 237
- References
- 28
- Citations by year
- 2026: 87 · 2025: 99 · 2024: 51
- FWCI
- 67.33
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, survodutide, glucagon receptor agonist, GLP-1 receptor agonists, dual agonist, weight loss, body weight, dose escalation, safety and tolerability, non-diabetic obesity, modified intention-to-treat analysis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon, Humans, Hypoglycemic Agents, Middle Aged, Obesity, Peptides, Treatment Outcome, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(23)00356-x
- The paper
- le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00356-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.